S&P 500 7,623.68 −0.52%
Nasdaq 25,955.34 −0.21%
S&P/TSX 35,788.18 −0.52%
Apple 347.73 −0.14%
Nvidia 210.96 −0.59%
Microsoft 524.51 +0.66%
Shopify 236.24 −0.07%
Royal Bank 281.77 −0.36%
CAD/USD 0.7141 −0.01%
CLOSED · 03:25 ET
Market ClerkRecap
Sat Oct 24 · markets closed6 signals on Oct 2394 insider buys this week · $48.3MCIRO short report next: Oct 30The week ahead

IRD

Opus Genetics, Inc.
NASDAQ · HEALTH CARE · PHARMACEUTICAL PREPARATIONS
3.47
−0.35 −9.16%
USD · close Oct 23

A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up

MKT CAP $288.7MP/E —DIV YIELD —FCF YIELD —REV TTM $9.9M −36.1%NET INCOME −$107.6MNET CASH $53.5M52W 1.74 – 6.07NEXT EARNINGS Nov 11 EST.SEC XBRL · TTM TO Invalid Date

Who holds it

SEC 13F · LATEST QUARTER PER FUND
None of the 15 tracked funds disclose IRD in their latest 13F. The funds we follow.

13F filings cover US-listed holdings and arrive up to 45 days after quarter end, so positions may have changed since.

Stakes of 5% or more

SCHEDULE 13D / 13G · LATEST PER HOLDER · TWO YEARS
No 13D or 13G filing on IRD in the last two years from the filings we read (13G only for companies we track; the sweep began Sep 2026).

A 13D means the holder crossed 5% with intent beyond passive ownership and had to state a purpose; a 13G is the passive version. Every new 13D on tracked companies.

Watch IRD. Know when insiders buy.
One email the day a filing lands. Free.